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Background: Whole-exome sequencing has shown that lung adenocarcinoma (LAC) can be driven by mutant
genes, including TP53, P16, and Smad4. The aim of this study was to clarify protein alterations of P53, P16, and
Smad4 and to explore their correlations between the protein alterations and clinical outcome.
Methods: We investigated associations among P53 mutant (P53Mut) expression, and P16 and Smad4 loss-of-expression,
with clinical outcome in 120 LAC patients who underwent curative resection, using immunohistochemical (IHC) methods.
Results: Of the 120 patients, 76 (63.3%) expressed P53Mut protein, whereas 54 (45.0%) loss of P16 expressed and 75
(62.5%) loss of Smad4 expressed. P53Mut expression was associated with tumor size (P = 0.041) and pathological
stage (P = 0.025). Loss of P16 expression was associated with lymph node metastasis (P = 0.001) and pathological stage
(P < 0.001). Loss of Smad4 expression was associated with tumor size (P = 0.033), lymph node metastasis (P = 0.014),
pathological stage (P = 0.017), and tumor differentiation (P = 0.022). Kaplan-Meier survival analysis showed that tumor
size (P = 0.031), lymph node metastasis (P < 0.001), pathological stage (P < 0.001), P53Mut protein expression (P = 0.038),
and loss of p16 or Smad4 expression (P < 0.001) were significantly associated with shorter overall survival(OS), whereas
multivariate analysis indicated that lymph node metastasis (P = 0.014) and loss of p16 or Smad4 expression (P < 0.001)
were independent prognostic factors. Analysis of protein combinations showed patients with more alterations had
poorer survival (P < 0.001). Spearman correlation analysis showed that loss of Smad4 expression inversely correlated
with expression of P53Mut (r = −0.196, P = 0.032) and positively with lost P16 expression (r =0.182, P = 0.047).
Conclusions: The findings indicate that IHC status of P53Mut, P16, and Smad4 may predict patient outcomes in LAC.
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Lung cancer is the leading cause of cancer death world-
wide [1], and the proportion of lung cancer patients with
lung adenocarcinoma (LAC) is reportedly increasing [2].
Survival rates for LAC have improved dramatically in
the last decade, owing to identification of driver muta-
tions in LAC [3]. For example, EGFR tyrosine kinase in-
hibitor have been approved for treatment of LACs that
carry EGFR gene mutations, which has greatly improved
the prognosis of such patients [4,5]. Discovery of genetic* Correspondence: xulin83cn@hotmail.com; hbshen@hotmail.com
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Identified driver gene alteration for LAC currently in-
cludes mutations of EGFR, KRAS, PIK3CA, BRAF, STK11,
DDR2, TP53, Smad4, P16, RET, and ALK, among others
[7-11]. As driver genes are found, their relationships to
each other and to patients’ prognoses must be verified.
Genetic alterations of P53, P16, and Smad4 have been
found in pancreatic cancer, and appear to be strongly as-
sociated with its malignant behavior [12-14]. In our pre-
vious study with a genetically engineered mouse model,
we found P53Mut’s potentially malignant gain-of-function
was promoted by inactivating the inhibitory actions of
transforming growth factor β (TGF-β), caused by down-
regulation of smad4, which in turn was synergistically
caused by P53Mut and deficient P16/P19. Although theseis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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is known about how they interact, or their combined ef-
fect on prognosis. Here, we investigated mutant P53,
P16, and Smad4 in LAC by immunohistochemical (IHC)
staining and correlated these mutations with clinicopath-
ological features and patients’ OS.
Methods
Patients and tissue samples
This study included 120 patients with LAC who under-
went surgical resection between January 2007 and March
2009 at the Nanjing Medical University-Affiliated Cancer
Hospital, Nanjing, China. All patients had complete med-
ical records and complete follow-up data. The last follow-
up date was March 2014. Patients who died of causes
other than LAC before this date were excluded. Their clin-
icopathological data were collected from medical records
and follow-up data were obtained through telephone in-
terviews or by consulting the police population informa-
tion system. These patients’ mean age was 59.4 years
(range: 35 to 85 years), including 58 men and 62 women.
Before their surgeries, all patients underwent CT scans
or B-ultrasonic examinations to exclude locoregional or
widespread metastases. All patients underwent radical re-
sections; no patients received radiotherapy or chemother-
apy before surgery. This study was approved by the Ethics
Committee of Nanjing Medical University.
IHC analyses
Specimens of primary LAC from 120 patients were cut
into 5-μm tissue sections and deparaffinized by routine
methods. The slides were steamed for 20 min in sodium
citrate buffer. After cooling for 5 min, the slides were
IHC stained for P53Mut, P16 and Smad4. At least five
different distinct regions of the primary tumor were
IHC-labeled for each case to evaluate for potential het-
erogeneity. IHC labeling was carried out using P53Mut
mouse monoclonal antibody (clone SC126 diluted 1:100,
Santa Cruz Biotechnology, Dallas, USA), CDKN2A/P16
rabbit monoclonal antibody (clone SC468 diluted 1:100,
Santa Cruz Biotechnology), and Smad4/Dpc4 mouse
monoclonal antibody (clone SC-7966, diluted 1:100,
Santa Cruz Biotechnology) as reported [15]. Labeling
was detected by adding biotinylated secondary anti-
bodies. Positive controls were taken from sections
known to be positive from pancreatic carcinoma speci-
mens. For the negative controls, 1% PBS was used in
place of primary antibodies. Results were evaluated inde-
pendently by two experienced pathologists. P53Mut was
considered positive when ≥10% of tumor cell nuclei
showed strong staining with a dark brown color. P16
and Smad4 were considered positive when ≥ 20% of
tumor cell cytoplasm and nuclei showed staining with a
brown color (Figure 1).Statistical analysis
Statistical analysis of group differences was performed
using χ2 tests. The 1-, 3-, and 5-year survival rates were
estimated using life tables; OS was estimated using the
Kaplan-Meier method, and the differences were assessed
by the log-rank test. Cox proportional hazards models
were generated for multivariate analysis. Correlation
analysis used the Spearman test. P < 0.05 was considered
statistically significant. Statistical analyses were per-
formed using SPSS software (version 17.0, SPSS).
Results
Clinicopathological features and outcome
Of the 120 patients (58 men and 62 women), 47 (39.2%)
were older than 60 years at the time of surgery; their mean
and median ages were 59.4 and 58 years, respectively. At
the last follow-up date (March 2014), 25 (20.8%) patients
were still alive. Median OS was 35.14 months, with 1-, 3-,
and 5-year survival rates of 61.0%, 39.0%, and 33.0%, re-
spectively. In all 120 patients, 24 (20.0%) had T1 tumors,
73 (60.8%) had T2 tumors, and 23 (19.2%) had T3/4 tu-
mors. Lymph node metastases were present in 49/120
(40.8%). We found 26.7% of tumors were well differenti-
ated, 34.1% were moderately differentiated, and 39.2%
were poorly differentiated. Only 13 (10.8%) patients had
pleural invasion. Of the 120 patients, 37 (30.8%), 47
(39.2%), 36 (30.0%), and 0 (0%) presented with the Union
for International Cancer Control stage I, II, III and IV dis-
ease, respectively (Table 1).
Protein alterations in LAC
Using IHC labeling, we detected positive P53Mut in 76 pa-
tients (63.3%), negative P16 in 54 patients (45.0%), nega-
tive Smad4 in 75 patients (62.5%) (Table 1), alterations of
all three proteins (P53mut+/P16-/Smad4-) in 28 (23.3%)
patients, and normal expression of the three proteins
(P53mut-/P16+/Smad4+) in 17 (14.2%) patients (Table 2).
Protein alterations and clinicopathological features
Positive IHC labeling of P53Mut was significantly linked to
tumor size (P = 0.041) and pathological stage (P = 0.025).
Negative P16 IHC labeling was significantly associated
with lymphatic metastasis (P = 0.001) and pathological
stage (P < 0.001). Negative Smad4 IHC labeling was asso-
ciated with tumor size (P = 0.033), lymph node metastasis
(P = 0.014), differentiation (P = 0.022), and pathological
stage (P = 0.017) (Table 1).
Clinicopathological features and OS
Univariate analysis results were based on log-rank tests of
clinicopathological characteristics in relation to OS. Tumor
size (P = 0.031), lymph node metastasis (P < 0.001), and
pathological stage (P < 0.001) were significantly associated
with shorter OS (Table 2).
Figure 1 P53Mut, P16, and Smad4 expression in lung adenocarcinoma, shown immunohistochemically (SP × 200). (A) P53Mut positive
staining detected in nucleus. (B) P16 positive staining detected in cytoplasm and nucleus. (C) Smad4 positive staining detected in cytoplasm
and nucleus.
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Loss of P16 and Smad4 IHC labeling was associated with
a significantly shorter OS (P < 0.001). There were signifi-
cant differences in positive labeling of P53Mut with regard
to OS (P = 0.038). Next, based on the number of altered
proteins, we classified the patients into eight groups:
P53mut−/P16+/Smad4− (n = 11); P53mut−/P16+/Smad4+
(n = 17); P53mut−/P16−/Smad4+ (n = 5); P53mut−/P16−
/Smad4− (n = 11); P53mut+/P16+/Smad4− (n = 25);
P53mut+/P16+/Smad4+ (n = 13); P53mut+/P16−/Smad4+
(n = 10); and P53mut+/P16−/Smad4− (n = 28). Kaplan-Table 1 Mutant P53, P16, and Smad4 expression in relation to
Mutant P53 expression P P16 expres
Negative (%) Positive (%) Negative (
Age ≤60 year 26 (35.6%) 47 (64.4%) 0.766 34 (46.6%)
Age >60 year 18 (38.3%) 29 (61.7%) 20 (42.6%)
Male 25 (43.1%) 33 (56.9%) 0.157 27 (46.6%)
Female 19 (30.6%) 43 (69.4%) 27 (43.5%)
Tumor size (cm)
T1 (≤3) 14 (58.3%) 10 (41.7%) 0.041 8 (33.3%)
T2 (>3 ≤ 7) 24 (32.9%) 49 (67.1%) 34 (46.6%)
T3/4 (>7) 6 (26.1%) 17 (73.9%) 12 (52.2%)
Lymph nodes
Negative 27 (38.0%) 44 (62.0%) 0.709 23 (32.4%)
Positive 17 (34.7%) 32 (65.3%) 31 (63.3%)
Differentiation
Well 16 (50.0%) 16 (50.0%) 0.188 13 (40.6%)
Moderate 13 (31.7%) 28 (68.3%) 14 (34.1%)
Poor 15 (31.9%) 32 (68.1%) 27 (57.4%)
Pleural invasion
Negative 39 (36.4%) 68 (63.6%) 0.887 47 (43.9%)
Positive 5 (38.5%) 8 (61.5%) 7 (53.8%)
Pathological stage
Stage I 20 (54.1%) 17 (45.9%) 0.025 11 (29.7%)
Stage II 15 (31.9%) 32 (68.1%) 17 (36.2%)
Stage III 9 (25.0%) 27 (75.0%) 26 (72.2%)
The italicized values indicate P values less than 0.05.Meier survival analysis showed that the P53mut−/
P16+/Smad4+ group had the longest OS and the P53
mut+/P16−/Smad4- group had the shortest OS (P < 0.001).
The higher number of altered proteins robustly reflected
major differences in survival outcome. The results showed
patients with more protein alterations had poorer survival
rates (Table 2, Figure 2).
Multivariate analyses of factors affecting OS
Multivariate models using Cox proportional hazards
analysis were conducted with the parameters that wereclinicopathological parameters (n = 120)
sion P Smad4 expression P
%) Positive (%) Negative (%) Positive (%)
39 (53.4%) 0.666 47 (64.4%) 26 (35.6%) 0.595
27 (57.4%) 28 (59.6%) 19 (40.4%)
31 (53.4%) 0.741 32 (55.2%) 26 (44.8%) 0.109
35 (56.5%) 43 (69.4%) 19 (30.6%)
16 (66.7%) 0.392 11 (45.8%) 13 (54.2%) 0.033
39 (53.4%) 45 (61.6%) 28 (38.4%)
11 (47.8%) 19 (82.6%) 4 (17.4%)
48 (67.6%) 0.001 38 (53.5%) 33 (46.5%) 0.014
18 (36.7%) 37 (75.5%) 12 (24.5%)
19 (59.4%) 0.077 15 (46.9%) 17 (53.1%) 0.022
27 (65.9%) 24 (58.5%) 17 (41.5%)
20 (42.6%) 36 (76.6%) 11 (23.4%)
60 (56.1%) 0.497 66 (61.7%) 41 (38.3%) 0.596
6 (46.2%) 9 (69.2%) 4 (30.8%)
26 (70.3%) <0.001 18 (48.6%) 19 (51.4%) 0.017
30 (63.8%) 28 (59.6%) 19 (40.4%)
10 (27.8%) 29 (80.6%) 7 (19.4%)
Table 2 Clinicopathological parameters and overall survival in 120 patients
Mean (month) Median (month)
N Estimate 95% CI Estimate 95% CI P
Age (year)
≤60 73 41.520 35.148 to 47.892 37.000 24.907 to 49.093 0.883
>60 47 40.396 32.890 to 47.902 30.000 17.931 to 42.069
Sex
M 58 41.563 34.672 to 48.454 36.000 18.585 to 53.415 0.917
F 62 40.535 33.685 to 47.385 30.000 17.461 to 42.539
Tumor size (cm)
T1 (≤3) 24 49.125 40.950 to 57.300 45.000 31.797 to 58.203 0.031
T2 (3 to 7) 73 41.959 35.673 to 48.245 35.000 17.325 to 52.675
T3/4 (>7) 23 28.587 17.986 to 39.188 15.000 10.340 to 19.660
Lymph nodes
Negative 71 50.437 44.488 to 56.387 49.000 39.870 to 58.130 <0.001
Positive 49 27.497 20.990 to 34.003 17.000 13.571 to 20.429
Differentiation
Well 32 48.869 40.548 to 57.190 49.000 33.785 to 64.215 0.067
Moderate 41 43.975 35.538 to 52.412 35.000 16.180 to 53.820
Poor 47 33.009 25.461 to 40.556 21.000 14.283 to 27.717
Pleural invasion
Negative 107 42.446 37.213 to 47.680 37.000 25.020 to 48.980 0.091
Positive 13 31.385 18.335 to 44.434 23.000 15.954 to 30.046
Stage
I 37 57.224 49.411 to 65.036 55.000 42.364 to 67.636 <0.001
II 47 39.400 31.965 to 46.836 30.000 20.613 to 39.387
III 36 27.111 19.609 to 34.613 16.000 11.296 to 20.704
Mutant P53
Negative 44 47.794 39.707 to 55.881 47.000 29.665 to 64.335 0.038
Positive 76 37.172 31.317 to 43.027 30.000 20.511 to 39.487
P16
Negative 54 28.352 22.689 to 34.014 20.000 14.399 to 25.601 <0.001
Positive 66 51.359 44.929 to 57.788 56.000 40.849 to 71.151
Smad4
Negative 75 30.185 25.074 to 35.297 21.000 15.346 to 26.654 <0.001
Positive 45 59.678 52.491 to 66.866 66.000 50.912 to 81.088
Gene expression combinations <0.001
P53mut−/P16+/Smad4− 11 43.364 27.766 to 58.961 47.000 13.553 to 80.447
P53mut−/P16+/Smad4+ 17 63.824 54.411 to 73.236 74.000 44.191 to 103.809
P53mut−/P16−/Smad4+ 5 53.800 33.542 to 74.058 49.000 38.265 to 59.735
P53mut−/P16−/Smad4− 11 22.000 14.791 to 29.209 21.000 14.746 to 27.254
P53mut+/P16+/Smad4− 25 41.451 31.906 to 50.997 32.000 12.416 to 51.584
P53mut+/P16+/Smad4+ 13 58.011 44.148 to 71.874 66.000 38.979 to 93.021
P53mut+/P16−/Smad4+ 10 52.100 38.216 to 65.984 54.000 27.658 to 80.342
P53mut+/P16−/Smad4− 28 18.185 14.057 to 22.313 15.000 12.976 to 17.024
The italicized values indicate P values less than 0.05.
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Figure 2 Changes in protein expression and overall survival (OS). (A) Patients’ postoperative OS curves by P53Mut expression. (B) Patients’
postoperative OS curves by P16 expression. (C) Patients’ postoperative OS curves by Smad4 expression. (D) Patients’ postoperative OS curves by
different protein expression combinations.
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log-rank tests. Multivariate analysis showed that lymph
node metastasis (relative risk (RR): 2.222, P = 0.014), nega-
tive Smad4 IHC labeling (RR: 0.269, P < 0.001) and nega-
tive P16 IHC labeling (RR: 0.360, P < 0.001) were independent
predictors of OS (Table 3).
Correlation analysis of P53mut, P16 and Smad4 expression
Spearman analysis indicated that Smad4 expression was
negatively correlated with P53mut expression (r = −0.196,
P = 0.032) and positively correlated with P16 expression
(r = 0.182, P = 0.047), whereas P16 expression and
P53mut expression showed no correlation (Table 4).
Discussion
The molecular basis of lung cancer is complex and het-
erogeneous. Over the last decades, identification ofdriver mutations in LAC has led to the development of
targeted agents, several of which are in clinical trials and
are already approved for clinical use [6].
Recent whole-exome sequencing studies of numerous
human cancers have conclusively shown TP53 to be the
most frequently mutated gene in human cancers [15,16].
The P53 protein and its downstream pathways are
important in preventing tumor formation, but TP53
mutation is common in cancers. Moreover, unlike other
tumor-suppressor genes that only lose their tumor-
suppressor functions, the P53Mut gene may endow its
mutant protein with new activities that actively promote
tumor progression and increased resistance to anticancer
treatments [17]. Because P53Mut proteins have longer
half-life than wild-type P53, which can accumulate in
the nucleus, we only can detect P53Mut proteins by IHC.
Although Ding et al. found that 45% of LAC patients
Table 3 Multivariate analysis of prognostic factors for
overall survival (n = 120)
Factors Relative risk 95% CI P
Tumor size 1.423 0.990 to 2.044 0.056
Status of lymph nodes metastasis 2.222 1.172 to 4.210 0.014
Pathological stage 1.075 0.706 to 1.636 0.735
Positive P53Mut labeling 1.320 0.834 to 2.091 0.236
Negative P16 labeling 0.360 0.226 to 0.572 <0.001
Negative Smad4 labeling 0.269 0.165 to 0.441 <0.001
The italicized values indicate P values less than 0.05.
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mutant P53 in LAC may still be conflicting. P53 alter-
ations are reported to predict poor survival in patients
with non-small cell lung cancer (NSCLC) [19-22]. How-
ever, Ahn et al. reported that P53Mut protein expression
did not correlate with OS in NSCLC [23]. In our study,
the P53Mut frequency was 63.3%, which was higher than
that previously reported. The results of univariate ana-
lyses showed that higher P53Mut IHC expression pre-
dicted shorter OS. However, the multivariate analysis
indicated that higher P53Mut expression did not independ-
ently predict poorer OS. Furthermore, mice that express
P53Mut reportedly have a more aggressive and metastatic
tumor profile than that of mice with null or wild-type P53
[24,25]. Conversely, Jackson et al. reported that P53Mut
protein in lung showed no detectable gain-of-function ac-
tivity [26]. Although the present study found no relation-
ship between P53Mut and lymph node metastasis, P53Mut
expression was linked to tumor size and pathological
stage. The role of TP53 mutations as a prognostic marker
in NSCLC were reported conflicting. This may be due to
the molecular heterogeneity and differing functional ef-
fects specific to various TP53 genotypes, methodological
issues related to the assessment of mutation status, and
design issues related to small sample size and nonhomo-




r 1.000 −0.132 −0.196
P - 0.150 0.032
P16
r −0.132 1.000 0.182
P 0.150 - 0.047
Smad4
r −0.196 0.182 1.000
P 0.032 0.047 -
The italicized values indicate P values less than 0.05; r, Pearson correlation.which these mutations occur, the initiating events and
other secondary molecular alterations, may matter as well.
Hence, a larger sample size and more complete experi-
ment methods will be required in the future to obtain reli-
able and consistent results.
P16 is an important tumor-suppressor gene that has
been found to affect cell-cycle by inactivating the cyclin-
dependent kinase inhibitor [27-29]. P16 alterations in
NSCLC were mainly homozygous deletions, promoter
hypermethylation and point mutations [30]. The relation-
ship between P16 expression and lung cancer is still un-
clear. Although some studies reported that P16 expression
increased in NSCLC [31,32], another found the P16 gene
to be a commonly inactivated tumor-suppressor gene in
NSCLC, and altered P16 and P53 genes to be frequently
found in the same tumors [30]. In this study, loss of P16
was linked to lymph node metastasis and pathological
stage, which accords with the study that found complete
P16 inactivation in advanced NSCLC [30].
Smad4 is a tumor-suppressor gene with a key role in
the TGF-β signaling pathway [33]. Because of its medi-
atory role in the growth-inhibitory effects of TGF-β in
normal cells and its loss in some tumors, Smad4 is con-
sidered a tumor-suppressor gene [34]. Alterations of
Smad4 gene were reported in pancreatic, colorectal, gas-
tric, esophageal, and breast tumors; its loss is associated
with tumorigenesis and progression [35-39]. However,
the role of Smad4 in LAC is unclear. NSCLC reportedly
features low Smad4 expression, which is closely corre-
lated with lymph node metastasis but not with histo-
logical type or differentiation [40]. Our study found the
loss of Smad4 was key to LAC occurrence and develop-
ment; our IHC results showed a 62.5% loss rate for
Smad4 in patients with LAC. Negative Smad4 labeling
was associated with tumor size, lymph node metastasis,
differentiation, and pathological stage, and patients with
Smad4 negative specimens had worse OS. Thus, reduced
Smad4 expression in LAC may predict poor prognosis.
We also found that patients with more protein alter-
ations had worse OS. Possibly, accumulated protein
alterations greatly influence LAC development; this
would also indicate that combinations of protein alter-
ations are more accurate predictors for patient outcome
than single alterations.
We used Spearman correlation analysis to investigate
the relationship among smad4, P53Mut, and P16. Although
expressions of Smad4 and P53Mut were inversely corre-
lated, Smad4 expression was positively correlated with
P16 expression. A previous study revealed that in SMMC-
7221 hepatocellular carcinoma cells, TGF-β inhibited pro-
liferation by upregulating P16 expression and increased
apoptosis by activating caspase 3 in a Smad4-dependent
manner [41]. Another study showed that low Smad4 ex-
pression is related to the high p53 expression in breast
Bian et al. World Journal of Surgical Oncology  (2015) 13:128 Page 7 of 8tumors [42]. As these results are similar to ours, we spec-
ulated that LAC could have a similar mechanism. In an-
other study with results that accorded with ours,
knocked-down P53 (using siRNA) reportedly increased
Smad4 activity and promoted apoptosis in MCF-7 breast
cancer cells [39]. Montserrat et al. found that P16 was a
commonly inactivated tumor-suppressor gene in NSCLC
and that P16 alterations and P53 mutations were fre-
quently found in the same tumor [30]. However, in this
paper, we found no correlation between P16 expression
and TP53 expression.
Conclusions
In conclusion, alterations of the P53, P16, and Smad4 pro-
teins were strongly associated with LAC malignancy of
LAC. Their IHC assessment at the time of diagnosis may
provide a new prognostic method, assisting in deciding
optimal treatment strategies for patients with LAC.
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